Testing effectiveness (Phase 2)Ended earlyNCT05128942
What this trial is testing
Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
Who this might be right for
Congenital Adrenal Hyperplasia21-OHD
Spruce Biosciences 67